Get the Stockscreener App
168.37
2.35%
3.87
After Hours:
168.55
0.18
+0.11%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $168.37, with a volume of 2.94M.
It is up +2.35% in the last 24 hours and down -5.02% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$164.50
Open:
$166.22
24h Volume:
2.94M
Relative Volume:
1.38
Market Cap:
$261.12B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
50.57
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
-11.05%
1M Performance:
-5.02%
6M Performance:
+79.14%
1Y Performance:
+139.43%
1-Day Range:
$166.21
$169.57
1-Week Range:
$164.45
$180.21
52-Week Range:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
168.37 | 262.83B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,156.63 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
247.02 | 620.51B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
244.11 | 438.16B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.61 | 306.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.80 | 292.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
Is AstraZeneca Quietly Rewriting Its Regulatory Story This Week? - Kalkine Media
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN - GlobeNewswire Inc.
AstraZeneca slides Tuesday, underperforms market - MarketWatch
Astrazeneca nabs PDE3/4 inhibitor for COPD in $2.1B Sino deal - BioWorld News
AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug - Pharmaceutical Technology
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical - Reuters
AstraZeneca To Acquire Lung Cancer Drug License For $1.5B - Law360
AstraZeneca stock holds steady as investors wait for a catalyst - Ad-hoc-news.de
AstraZeneca Secures Licensing Deal for Zegfrovy (AZN) - GuruFocus
AstraZeneca (NASDAQ: AZN) signs global Zegfrovy lung cancer deal - Stock Titan
Is AstraZeneca (LSE:AZN) Worth Watching After Its Latest Regulatory Wins? - Kalkine Media
AstraZeneca (AZN) Expands Oncology Portfolio with $600M Lung Can - GuruFocus
ASTRAZENECA : JP Morgan maintains a Buy rating - marketscreener.com
AstraZeneca to pay up to $1.5bn for global righ... - Pluang
AstraZeneca Secures Global Rights to Lung Cancer Therapy in $600m Deal (AZN) - Yahoo Finance UK
AstraZeneca Enters Exclusive Global License Agreement Fornovel Oral EGFR Inhibitor Zegfrovy for Lung Cancer with Dizal Pharmaceutical - marketscreener.com
Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape - Yahoo Finance Singapore
AstraZeneca buys worldwide rights to cancer drug for USD1.5 billion - London South East
Dizal Pharmaceutical Co., Ltd. Grants Astrazeneca plc Worldwide Rights to Develop and Commercialise Zegfrovy - marketscreener.com
Astrazeneca strikes exclusive licensing deal with Dizal Pharmaceutical - Sharecast.com
AstraZeneca to pay up to $1.5bn for global rights to lung cancer pill - Proactive financial news
AstraZeneca acquires rights to Dizal's Zegfrovy - marketscreener.com
AstraZeneca pays $600m for Chinese lung cancer drug rights By Investing.com - Investing.com Nigeria
Astrazeneca Secures Global Rights To Zegfrovy In EGFR-mutated Lung Cancer - DirectorsTalk Interviews
AstraZeneca Secures Exclusive Global License for Zegfrovy from Dizal Pharmaceutical in $1.5 Billion Deal to Enhance Lung Cancer Treatment Portfolio - Kalkine Media
REGAstraZeneca PLCAstraZeneca licenses novel EGFR inhibitor - TradingView
AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical - AstraZeneca
AstraZeneca falls Monday, underperforms market - MarketWatch
HSBC Downgrades AstraZeneca to Hold Rating, Cuts PT - marketscreener.com
AstraZeneca Downgraded by HSBC as Wainua Trial Miss Clouds Near-Term Outlook (AZN) - Yahoo Finance UK
HSBC downgrades AstraZeneca to 'hold' after key heart disease trial failure - Pluang
HSBC downgrades AstraZeneca after key trial failure - Proactive financial news
UBS stays positive on AstraZeneca ahead of second-quarter results - Proactive financial news
AstraZeneca stock dips as HSBC downgrades stock on ’tough path ahead’ By Investing.com - Investing.com South Africa
ASTRAZENECA : Buy rating from UBS - marketscreener.com
ASTRAZENECA : Deutsche Bank reaffirms its Sell rating - marketscreener.com
Berenberg Sticks With Its Confidence in AstraZeneca, But Lowers Its Target - marketscreener.com
HSBC downgrades AstraZeneca stock rating on trial concerns By Investing.com - Investing.com South Africa
ASTRAZENECA : Buy rating from Berenberg - marketscreener.com
AstraZeneca CEO: ‘Biology will catch up with me at some point’ - Financial Times
AstraZeneca erases billions after sobering reveal - thestreet.com
AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage - TradingView
AstraZeneca stock steadies on its global drug pipeline - ad-hoc-news.de
AstraZeneca's (AZN) Vaccine Influence Under Scrutiny Amid New Ad - GuruFocus
Why Did AstraZeneca (AZN) Stock Dip More Than the Market Today - Kavout | AI
Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts - Yahoo Finance
AstraZeneca's $27 Billion TTR Wipeout Hands Alnylam the Market — But Its Own Trial Has the Same Flaw - finance.biggo.com
SERAFA-1 Trial Update: AstraZeneca and Icon Deepen Their Breast Cancer Bet - TipRanks
AstraZeneca slips Friday, underperforms market - MarketWatch
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain - Benzinga
AstraZeneca PLC Stock (AZN) Moved Down by 3.50% on Jul 10: Key Drivers Unveiled - TradingKey
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):